This one-stop reference is the first to present the complete picture --
covering all relevant organisms, from single cells to mammals, as well
as all major disease areas, including neurological disorders, cancer and
infectious diseases.
Addressing the needs of the pharmaceutical industry, this unique
handbook adopts a broad perspective on the use of animals in the early
part of the drug development process, including regulatory rules and
limitations, as well as numerous examples from real-life drug
development projects.
After a general introduction to the topic, the expert contributors from
research-driven pharmaceutical companies discuss the basic
considerations of using animal models, including ethical issues. The
main part of the book systematically surveys the most important disease
areas for current drug development, from cardiovascular to endocrine
disorders, and from infectious to neurological diseases. For each area,
the availability of animal models for target validation, hit finding and
lead profiling is reviewed, backed by numerous examples of both
successes and failures among the use of animal models. The whole is
rounded off with a discussion of perspectives and challenges.
Key knowledge for drug researchers in industry as well as academia.
